Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — 36th Annual J.P. Morgan Healthcare Conference 2018
25 slides from Dr. Reddy's Laboratories's conference presentation, Jan 9, 2018
Slide 1: 36th Annual J.P. Morgan Healthcare Conference
36th Annual J. P. Morgan Healthcare Conference January 9, 2018 Dr. Reddy’s Laboratories Limited Hyderabad, India BSE: 500124 | NSE: DRREDDY | NYSE: RDY
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Contents
Contents Our Purpose Company Overview Recent Business Highlights Growth Roadmap Optimistic Future 3
Slide 4: Our Purpose
Our Purpose We accelerate access to affordable and innovative medicines Because Good Health Can’t Wait.
Slide 5: Our Purpose Guides Our Customer Value Proposition
Our Purpose Guides Our Customer Value Proposition Leading to Specific Strategic Choices PURPOSE OUR PROMISES Bringing expensive medicine within reach We accelerate access to affordable medicines because Addressing unmet patient needs Good Health Helping patients manage disease better Can’t Wait. Ena
Slide 6: Company Overview
COMPANY OVERVIEW e O
Slide 7: Multidimensional business model to sustain long-term growth
Multidimensional business model to sustain long-term growth UNBRANDED BRANDED PROPRIETARY (US + EU) (EM + INDIA) PRODUCTS • Continued growth for mega Current • Maximize the base business • Monetize the complex/ limited brands through patient centric initiatives revenues through volume competition as
Slide 8: Formulation manufacturing infrastructure and capabilities
Formulation manufacturing infrastructure and capabilities DOSAGE FORM CAPABILITIES DETAILS 10 Facilities out of which Tablets, Capsules, Pellets, Oral Solids bi-layers, Modified / • 4 US FDA approved of which 2 are located in USA (22 bn pills annual) Extended release, ODTs • 3 MHRA approved 3 Facili
Slide 9: Globalized R&D to Access the Right Talent
Globalized R&D to Access the Right Talent to Solve Complex Scientific Challenges Complex Complex Injectable Chemistry Centre Centre of of Excellence Excellence Cambridge, UK Leiden, Netherlands Canada Germany UK USA Italy Product Development Complex Centers Generics & Hyderabad & Bangalore Proprieta
Slide 10: Recent Business Highlights
Recent Business Highlights 10
Slide 11: Delivering affordable generic alternatives in Unbranded Markets
Delivering affordable generic alternatives in Unbranded Markets 12 NEW PRODUCTS LAUNCHED IN NORTH AMERICA SO FAR THIS FISCAL Sevelamer Carbonate Tablets launched in the U.S. Market • Affordable alternative for complex, limited-competition product • Fourth limited-competition launch this fiscal year
Slide 12: Biosimilars and small molecule Oncology assets fueling global expansion
Biosimilars and small molecule Oncology assets fueling global expansion Successful launches of Oncology products in EM and EU • Colombia, Brazil, Algeria, Spain, Italy Reditux™ paving the way for the entry of upcoming Biosimilar assets in new markets • Currently approved in 17 countries and availabl
Slide 13: Patient-centric Initiatives in Emerging Markets
Making a difference through Patient-centric Initiatives in Emerging Markets Our first wave of patient-centric packaging has been received well Four India Star awards for patient-centric packaging Push Tab feature in carton to (selected from 622 entries); now qualify for Asia star and Integrated fl
Slide 14: Addressing unmet needs in Derma and Neurology
Addressing unmet needs in Derma and Neurology Commercial Updates First set of launches Zembrace™ and Sernivo™ ramping up well, continue to focus on accelerating the commercial business’ path to profitability Promius Pharma recognized as an emerging R&D driven commercial organization in the neuro
Slide 15: Our Quality Journey
Our Quality Journey WE ARE COMMITTED TO EXCELLENCE IN QUALITY AND TO BEING THE BEST IN THE INDUSTRY U.S. FDA Audit Updates Sites Previously on Warning Letter CTO 5: Three observations in audit - Received EIR CTO 6: Two Observations in audit – EIR Awaited FTO 7 Sterile Plant: Received EIR: compliance
Slide 16: Growth Roadmap
Growth Roadmap e « ) )
Slide 17: North America Generics: Growth driven by limited competition products
North America Generics: Growth driven by limited competition products 2017 2021 • More than 50% of revenues to come from • Oral solid dosages account for almost 80% of Injectables, Topicals and other complex Portfolio the current revenues dosage forms • Injectables accounting for 20% of the revenues
Slide 18: India & Emerging Markets: Growth driven by patient centric initiatives
India & Emerging Markets : Growth driven by patient centric initiatives 2017 2021 • Portfolio augmentation and productivity improvement • Focus on mega brands • Step-up in Chronic and Super-specialty therapies expansion • India Strategic business development and M&A efforts • Improvement in new • Di
Slide 19: Biologics: Maximizing value of current assets
Biologics: Maximizing value of current assets in near to mid-term while pursuing global development EU/US approval enabling studies initiated for pegfilgrastim Rituximab and bevacizumab approval enabling studies for EU/US expected to be BIOLOGICS REVENUE HAS GROWN AT APPROX. initiated in next 4 - 6
Slide 20: Biologics: Creating substantial value in long term
Biologics: Creating substantial value in long term from new portfolio choices while driving R&D productivity 6 commercial products; > 50 filings across 14 major countries FY20 Product Portfolio 5 new products in clinical development Emerging Markets Revenue: ~ $150Mn FY20 Business Profile Developed
Slide 21: Proprietary Products: Aspiring to build a $400 million business by FY22
Proprietary Products: Aspiring to build a $400 million business by FY22 through a low-risk innovation model Specialty Dermatology Franchise • Established with the goal to address unmet needs of specific patient segments in • 3 Products approved; 1 asset commercialized Dermatology & Neurology and 2 l
Slide 22: Key Priorities
KEY PRIORITIES e « ) @
Slide 23: 2018 Key Priorities
2018 Key Priorities Strengthening Manufacturing & Quality Create culture encouraging Transparency and Compliance Creating Leaner and Flexible cost structures Focus on Manufacturing and R & D Network Rationalization, Improving Plant Operating Efficiency, R&D Productivity and Portfolio Optimizatio
Slide 24: Good Health Can't Wait.
Good Health Can’t Wait.
Slide 25: Contacts
Contacts Investor relations Media relations Saunak Savla Calvin Printer saunaks@drreddys.Com calvinprinter@drreddys.Com (Ph: +91-40-49002135) (Ph: +91-40-49002121) About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committ
Dr. Reddy's Laboratories — 36th Annual J.P. Morgan Healthcare Conference 2018 on 6ix